APA (7th ed.) Citation

Rischin, D., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro Jr, G., . . . Chirovsky, D. (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128, N.PAG. https://doi.org/10.1016/j.oraloncology.2022.105815

Chicago Style (17th ed.) Citation

Rischin, Danny, et al. "Pembrolizumab Alone or with Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Health-related Quality-of-life Results from KEYNOTE-048." Oral Oncology 128 (2022): N.PAG. https://doi.org/10.1016/j.oraloncology.2022.105815.

MLA (9th ed.) Citation

Rischin, Danny, et al. "Pembrolizumab Alone or with Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Health-related Quality-of-life Results from KEYNOTE-048." Oral Oncology, vol. 128, 2022, p. N.PAG, https://doi.org/10.1016/j.oraloncology.2022.105815.